Oruka Therapeutics (ORKA) Cash & Current Investments (2010 - 2026)

Oruka Therapeutics' Cash & Current Investments history runs 17 years deep, the most recent figure standing at $831.2 million for Q1 2026.

• On a quarterly basis, Cash & Current Investments rose 138.09% year-over-year to $831.2 million in Q1 2026; TTM through Mar 2026 was $831.2 million, a 138.09% increase from a year earlier, with the FY2025 full-year figure at $334.9 million, down 10.86% from the prior year.
• Cash & Current Investments advanced to $831.2 million in Q1 2026 per ORKA's latest filing, from $334.9 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $831.2 million in Q1 2026 and bottomed at $33.3 million in Q2 2024.
• The 5-year median for Cash & Current Investments is $46.4 million (2022), against an average of $222.8 million.
• Across the five-year window, Cash & Current Investments slipped 26.7% in 2022 and jumped 947.94% in 2024, its largest moves.
• Year by year, Cash & Current Investments stood at $42.4 million in 2022, then dropped by 11.81% to $37.4 million in 2023, then jumped by 903.57% to $375.6 million in 2024, then dropped by 10.86% to $334.9 million in 2025, then soared by 148.21% to $831.2 million in 2026.
• Per Business Quant, the three latest ORKA Cash & Current Investments figures stand at $831.2 million (Q1 2026), $334.9 million (Q4 2025), and $756.6 million (Q3 2025).